Clinical Trial Update: Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) [Phase 3]

View source ↗

Summary

Phase 3 trial of sibeprenlimab in immunoglobulin A nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Sibeprenlimab

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Immunoglobulin A Nephropathy | Phase 3 | Status: COMPLETED